Skip to main content

Table 1 Patient characteristics of the clinical trials reviewed

From: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

Study N F/M Age (Mean) Histology (N) TNM Stage (N) Quality of Life Invention Group (N) Group 1 (N) Group 2 (N) End point
Wang JW 2005[11] 486 140/346 18-75 SCC (129) LAC (165) Others (28) IIIA (51) IIIB (81) IV (185) ECGO NPE versus NP + placebo 322 164 RR, DCR, TTP, SI, AEs
Yang L 2005[12] 87 28/59 37-76 SCC (34) LAC (50) Others (3) III (32) IV (55) ECGO NPE versus NP 57 33 RR, DCR, SI, AEs
Cai L 2007[13] 71 25/46 NA SCC (27) LAC (32) Others (12) IIIA (9) IIIB (33) IV (29) KPS NPE versus NP 39 32 RR, DCR, AEs
Mu HY 2009[14] 62 22/40 42-75 SCC (28) LAC (34) IIIB (28) IV (34) KPS NPE versus NP (16) TPE versus TP (6) PPE versus PP (8) 32 30 RR, DCR, SI, AEs
Liao HY 2009[15] 85 32/53 36-72 SCC (36) LAC (49) IIIB (32) IV (53) KPS GPE versus GP 30 55 RR, DCR, OYS, AEs
Zang T 2009[16] 104 36/68 42-68 NA IIIB (58) IV (46) ECGO GPE versus GP 48 56 RR, DCR, SI, AEs
Liu J 2009[17] 62 17/45 29-68 SCC (38) LAC (24) III (37) IV (25) KPS NPE + RT versus NP + RT 31 31 RR, DCR, TTP, AEs
Ma JB 2009[18] 46 11/35 38-73 SCC (31) LAC (15) IIIA (26) IIIB (20) ECGO NPE + RT versus NP + RT 23 23 RR, DCR, TTP, AEs
Shi GY 2009[19] 462 162/300 20-74 SCC (190) LAC (252) Others (20) IIIA (92) IIIB (144) IV (226) ECGO GPE versus GP 308 154 RR, DCR, TTP, SI, AEs
Han BH 2011[20] 122 35/87 28-78 SCC (37) LAC (78) Others (7) IIIB (43) IV (79) ECGO TCE versus TC + placebo 61 61 RR, DCR, AEs
Zhao X 2011[21] 69 23/46 35-73 SCC (34) LAC (25) Others(10) IIIB (11) IV (58) ECGO GPE versus GP 33 36 RR, DCR, AEs
Hu HT 2011[22] 89 21/68 41-70 SCLC (89) NA KPS TPE versus TP 45 44 RR, DCR, AEs
Wen F 2011[23] 84 27/57 54-75 SCC (36) LAC (44) Others (4) NA KPS NPE versus NP 43 41 RR, DCR, AEs
Zhang H 2011[24] 56 15/41 36-75 SCC (18) LAC (33) Others (5) IIIB (32) IV (25) KPS NPE versus NP (2) GPE versus GP (15) TPE versus TP (11) 28 28 RR, DCR, TTP, OYS, AEs
Chen Q 2011[25] 68 27/41 42-75 SCC (20) LAC (44) Others (4) IIIA (15) IIIB (41) IV (12) NA GPE versus GP 33 35 RR, DCR, SI
  1. AEs , adverse effects; DCR, disease control rate; ECGO, eastern cooperative oncology group; F/M, female/male; GP, gemcitabine + cisplatin; GPE, gemcitabine + cisplatin + Endostar; Group 1, Endostar combined with PBDC; Group 2, PBDC alone; KPS, Karnofsky physical status score; LAC, lung adenocarcinoma; N, number of patients; NA, not available; NP, vinorelbine + cisplatin; NPE, vinorelbine + cisplatin + Endostar; OYS, one-year survival rate; PP, paclitaxel + cisplatin; PPE, paclitaxel + cisplatin + Endostar; RR, response rate; RT, radiotherapy; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer; SI, symptom improvement; TC, paclitaxel + carboplatin; TCE, paclitaxel + carboplatin + Endostar; TP, docetaxel + cisplatin; TP, TPE, docetaxel + cisplatin + Endostar; TTP, time to progression;